Premium
Early cutaneous eruptions after oral hydroxychloroquine in a lupus erythematosus patient: A case report and review of the published work
Author(s) -
Matsuda Tomoko,
Ly Nhung Thi My,
Kambe Naotomo,
Nguyen Chuyen Thi Hong,
UedaHayakawa Ikuko,
Son Yonsu,
Okamoto Hiroyuki
Publication year - 2018
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/1346-8138.14156
Subject(s) - hydroxychloroquine , medicine , dermatology , adverse effect , lupus erythematosus , drug reaction , systemic lupus erythematosus , cutaneous lupus erythematosus , drug , immunology , covid-19 , pharmacology , disease , antibody , infectious disease (medical specialty)
Hydroxychloroquine ( HCQ ) is an effective treatment of lupus erythematosus. Although adverse effects, mainly gastrointestinal and cutaneous manifestations, are rare, they may result in the cessation of medication in some patients with severe reactions. Therefore, the evaluation of a patient's condition is important for a dermatologist to decide whether to cease or continue HCQ . We herein report a case of a 36‐year‐old Japanese woman with systemic lupus erythematosus and cutaneous eruptions caused by the p.o. administration of HCQ . Because she wanted to continue the medication and had only mild cutaneous eruptions without any adverse effects in other organs, we continued HCQ with careful monitoring. All cutaneous eruptions disappeared within 1 week. We also reviewed published case reports on skin lesions that developed after HCQ treatments, and propose strategies for early cutaneous eruptions after HCQ treatments. When the cutaneous reactions are mild without any reactions in other organs, withdrawal of the drug is not required. However, when cutaneous eruptions are accompanied by some common reactions, HCQ needs to be stopped for a period of time and may subsequently be carefully re‐administrated.